obesity drug news today glp-1 2025 sep 30 Alarming rise in weight loss overdoses Dozens of new obesity drugs

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 ReceptorDependent and Independent Pathways

New England Journal of Medicine , 2022;387(3):205-216

p=0.61 not significant ;), both the control and the I-M-150847 treated group has similar body-weight gain

B vitamins may help, as gut bacteria are involved in B vitamin synthesis, and changes to the microbiome can affect availability

GLP-1 agonists appear to influence reward-related pathways beyond appetite control

Abstract Glucagon-like peptide 1 (GLP-1) receptor agonists are revolutionizing obesity and type 2 diabetes treatment, delivering remarkable weight loss outcomes